Completed PHASE2 INTERVENTIONAL 1-arm NCT00530816

Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma

An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Sponsor: Amgen

Interventions carfilzomib

Updated 8 times since 2017 Last updated: Apr 28, 2017 Started: Sep 30, 2007 Primary completion: Jan 31, 2013 Completion: Jul 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00530816, this PHASE2 trial focuses on Multiple Myeloma and remains completed. Sponsored by Amgen, it has been updated 8 times since 2007, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2017 — Jun 2018 [monthly]

Completed PHASE2
Feb 2017 — Jun 2017 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akron, United States , Amarillo, United States , Ann Arbor, United States , Atlanta, United States , Austin, United States , Beverly Hills, United States , Calgary, Canada , Canton, United States , Chicago, United States , Cleveland, United States and 20 more locations